Abbott Laboratories, a pharmaceutical company, has ended its business relationship with the chairman of the Conservative Political Action Coalition (CPAC) after he criticized the public destruction of property condoned by Black Lives Matter (BLM). Abbott Laboratories scored a 90 on the 2023 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. By complying with the HRC’s controversial demands, Abbott Laboratories increases the risk of dividing employees, alienating customers and harming shareholders. The company covers transgender-related medical costs for its employees and their children and provides specific sexual orientation and gender identity-based benefits. It also uses sex and gender ideology criteria in employee recruitment, vendor selection, marketing, and philanthropic support. The company forces employees to undergo multiple ideological trainings and uses its reputation, corporate funds, and political influence to support controversial sex and gender ideologies, organizations, and legislation. Abbott is a signatory of the Business Roundtable's 2019 Statement on the Purpose of Corporation, which promotes stakeholder capitalism. The company is a copper sponsor of Out & Equal and a corporate partner of the National LGBT Chamber of Commerce. The company requires its employees complete unconscious bias training and has donated to a Planned Parenthood Clinic. For these reasons, Abbott Laboratories receives a High Risk rating.